Medical/Pharmaceuticals News & Press Release Distribution

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and toripalimab in patients with advanced solid tumors TORCH-2 is the world's first clinical study evaluating the combination of a dual mTORC1/2 inhibitor and an anti-PD-1 monoclonal antibody SHANGHAI ...

2022-06-01 08:30 2249

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

SAN FRANCISCO and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-06-01 08:00 2630

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

Kemin Food Technologies - Asia Introduces Antimicrobial Disinfectant Solutions KEEPER™ and OXINE™

Latest product lines address safety at the start by treating food, water and the preparation space for food SINGAPORE, June 1, 2022 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world w...

2022-06-01 08:00 2717

Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia

Australians living with migraine can now come 'out of the dark' with Avulux migraine lenses DANDENONG SOUTH, Australia, June 1, 2022 /PRNewswire/ -- The world's first clinically proven lens for migraine and light sensitivity management is now available through eye-care practitioners inAustralia....

2022-06-01 05:00 2193

Avulux and CR Surfacing partner to make innovative migraine & light sensitivity lenses available through eye-care practitioners across Australia

CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights

SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2021 full-year financial results a...

2022-06-01 00:35 5360

Toku Eyes, Developer of an AI Platform That Accurately Identifies Risk of Heart Attack Using an Eye Image, Expands to The US

With Toku Eyes' artificial intelligence platform, the eye is not only the window to the soul — it is now a window to the state of your health AUCKLAND, New Zealand, May 31, 2022 /PRNewswire/ -- Toku Eyes, the New Zealand -based developer of a multi-modal artificial intelligence platform for instan...

2022-06-01 00:00 2038

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 2743

QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...

2022-05-31 22:30 1911

BIOMERICS ANNOUNCES EXPANSION INTO IRELAND

Expands High-Performance Balloon Design & Development Capabilities in Galway SALT LAKE CITY, May 31, 2022 /PRNewswire/ -- Biomerics, the leading vertically integrated medical device contract manufacturer serving the interventional device market, has today announced the opening of a 2,000 sq. f...

2022-05-31 22:05 3491

BIOMERICS ANNOUNCES EXPANSION INTO IRELAND

Nalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx Core

SINGAPORE, May 31, 2022 /PRNewswire/ -- Nalagenetics has just completed CE-marking for one of the reporting modules of its Clinical Decision Support (CDS) software. The registration enables its software to be marketed in Europe and support further approval inSoutheast Asia, where it aims to gain...

2022-05-31 21:09 2868

Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine

NEW YORK, May 31, 2022 /PRNewswire/ -- Rensselaer Polytechnic Institute and the Icahn School of Medicine atMount Sinai recently announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science ...

2022-05-31 21:00 2440

Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine

MGI and King Abdullah International Medical Research Center Announce Partnership for Genomic Research

The new agreement will enable cutting-edge research aimed at preventing disease and improving health while supporting specialized training of healthcare professionals and scientists. RIYADH, Saudi Arabia, May 31, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) and King...

2022-05-31 20:33 1973

Volition Achieves CE Mark for Nu.Q® NETs Test

to aid the detection and evaluation of diseases associated with NETosis AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluat...

2022-05-31 20:00 2894

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...

2022-05-31 20:00 1482

GBM AGILE OPENS TO PAXALISIB IN EUROPE

SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm inEurope. University Hospital Zurich...

2022-05-31 19:20 3044

Illuccix® Granted Transitional Pass-Through Payment Status

INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...

2022-05-31 19:00 1153

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

MONTREAL, May 31, 2022 /PRNewswire/ -- Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye tracking technology for people living with...

2022-05-31 18:00 1414

Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO

SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...

2022-05-31 17:56 622

Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease

SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...

2022-05-31 11:30 1378

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...

2022-05-31 08:08 1209